deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT00453635

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

A Multicenter Randomized Phase II Study of First Line Treatment With Sequential Administration of Docetaxel, Carboplatin and Herceptin Versus the Administration of Vinorelbine and Herceptin Combination in HER-2 Positive Patients With Metastatic Breast Cancer

Sponsor: Hellenic Oncology Research Group

Conditions Breast Cancer
Interventions Carboplatin Docetaxel Herceptin Vinorelbine
Updated 6 times since 2017 Last updated: Mar 12, 2012 Started: Dec 31, 2003 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to poor accrual

Other terminated trials from Hellenic Oncology Research Group

More terminations from Hellenic Oncology Research Group

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

Listed as NCT00453635, this PHASE2 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by Hellenic Oncology Research Group, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 11 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hellenic Oncology Research Group
  • University Hospital of Crete
Data source: Hellenic Oncology Research Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations